HomeCompareTRSBF vs CL

TRSBF vs CL: Dividend Comparison 2026

TRSBF yields 1.22% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRSBF wins by $9.04M in total portfolio value· pulled ahead in Year 2
10 years
TRSBF
TRSBF
● Live price
1.22%
Share price
$2.61
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.08M
Annual income
$7,845,769.56
Full TRSBF calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — TRSBF vs CL

📍 TRSBF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRSBFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRSBF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRSBF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRSBF
Annual income on $10K today (after 15% tax)
$103.69/yr
After 10yr DRIP, annual income (after tax)
$6,668,904.13/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, TRSBF beats the other by $6,664,312.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRSBF + CL for your $10,000?

TRSBF: 50%CL: 50%
100% CL50/50100% TRSBF
Portfolio after 10yr
$4.56M
Annual income
$3,925,585.76/yr
Blended yield
86.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

TRSBF
No analyst data
Altman Z
6.9
Piotroski
8/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRSBF buys
0
CL buys
0
No recent congressional trades found for TRSBF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRSBFCL
Forward yield1.22%2.43%
Annual dividend / share$0.03$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28.6%
Portfolio after 10y$9.08M$40.8K
Annual income after 10y$7,845,769.56$5,401.96
Total dividends collected$8.96M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: TRSBF vs CL ($10,000, DRIP)

YearTRSBF PortfolioTRSBF Income/yrCL PortfolioCL Income/yrGap
1$10,944$243.97$11,012$312.01$68.00CL
2← crossover$12,209$499.06$12,196$412.95+$13.00TRSBF
3$14,104$1,040.65$13,599$549.66+$505.00TRSBF
4$17,339$2,247.09$15,288$736.64+$2.1KTRSBF
5$23,716$5,163.36$17,353$995.28+$6.4KTRSBF
6$38,577$13,200.74$19,926$1,357.80+$18.7KTRSBF
7$81,413$40,135.71$23,194$1,873.82+$58.2KTRSBF
8$245,435$158,323.22$27,439$2,621.52+$218.0KTRSBF
9$1,154,758$892,143.08$33,088$3,727.38+$1.12MTRSBF
10$9,081,361$7,845,769.56$40,806$5,401.96+$9.04MTRSBF

TRSBF vs CL: Complete Analysis 2026

TRSBFStock

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Full TRSBF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this TRSBF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRSBF vs SCHDTRSBF vs JEPITRSBF vs OTRSBF vs KOTRSBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.